ASND1N Stock Chart & Stats
$4270.00
$0.00(0.00%)
At close: 4:00 PM EDT
$4270.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3,330.61 - $4,615.10
Previous CloseN/A
Volume0.00
Average Volume (3M)12.00
Market Cap
$284.62B
Enterprise Value$17.81K
Total Cash (Recent Filing)$811.92M
Total Debt (Recent Filing)$449.89M
Price to Earnings (P/E)18.5
Beta0.02
Next Earnings
Nov 11, 2026EPS Estimate
18.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.10
Shares Outstanding62,376,846
10 Day Avg. Volume36
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5,395.58Price Target Upside26.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)239.84
Revenue Forecast (FY)$22.77B
Bulls Say, Bears Say
Bulls Say
Commercial GrowthRapid growth from marketed rare-disease products demonstrates strong commercial execution and expanding patient adoption. YORVIPATH is becoming a substantial recurring revenue base, while SKYTROFA and YUVIWEL provide additional product diversification.
TransCon PlatformThe TransCon platform supports multiple long-acting therapies across rare endocrine and other areas. Ongoing partnerships, clinical progress and regular planned filings could create durable opportunities for label expansion, new products and licensing value.
Cash And Capital StrengthA sizable cash balance, debt-free financing position and strong recent cash conversion provide flexibility to fund launches, clinical development and manufacturing. This reduces dependence on near-term capital markets while the commercial portfolio scales.
Bears Say
Earnings DurabilityThe recent profitability inflection is not yet proven across a full cycle. Earlier losses, negative cash flow and periods of negative equity indicate that earnings and capital strength have historically been volatile, increasing execution and sustainability risk.
One-Time Profit SupportReported earnings materially benefited from a nonrecurring regulatory asset sale, so they overstate the underlying operating run rate. Future profitability must instead be supported by product sales and operating leverage, making normalized performance important.
Regulatory And Cost RiskHeavy investment is necessary for launches and pipeline expansion but can pressure normalized margins if revenue growth slows. In parallel, IP proceedings and confirmatory requirements could restrict commercialization or label durability for important products.
Ascendis Pharma News
ASND1N FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $3330.61 and its highest was $4615.10 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $284.62B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Nov 11, 2026 which is in 61 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Aug 13, 2026. The company reported $55.859 earnings per share for the quarter, beating the consensus estimate of $29.548 by $26.311.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is 18.36.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 62,376,846 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of $55.859 in its last earnings report, beating expectations of $29.548. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in MX:ASND1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5,395.58 (26.36% Upside)
$5,395.58 (26.36% Upside)
Blogger Sentiment
Neutral
MX:ASND1N Sentiment 50%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth $6.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
104.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
ASND1N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear early successes: double-digit top-line expansion with EUR 315 million in product revenue, blockbuster-level performance from YORVIPATH (EUR 252 million), a successful SKYTROFA base (>20,000 patients), and a promising early U.S. launch for YUVIWEL with rapid enrollments and reimbursement approvals. Robust clinical readouts (COACH arm-span gains) and progressing partnerships reinforce long-term upside. Offsetting these positives were elevated R&D and SG&A spending, reliance on a one-time PRV sale to bolster reported profit (non-IFRS net profit materially lower at EUR 61 million), and legal/regulatory uncertainties (U.S. IP dispute and confirmatory trial dependence). Overall, highlights outweigh the lowlights given accelerating commercial traction, a strong cash position and no debt, but investors should monitor expense trajectory and the legal/regulatory developments.View all MX:ASND1N earnings summariesASND1N Stock 12 Month Forecast
Average Price Target
$5,395.58
▲(26.36% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ultragenyx Pharmaceutical
―
Xeris Pharmaceuticals
―
Crinetics Pharmaceuticals
―
MBX Biosciences, Inc.
―